A randomized phase 2 trial of berzosertib plus carboplatin in pretreated mCRPC stopped for futility amid fewer responses and more high-grade toxicity than the control arm.
|Videos|April 28, 2011
Dr. Crawford on Alternatives to Biopsy in Prostate Cancer
Author(s)E. David Crawford, MD
Dr. Crawford Discusses Alternatives to Biopsy in Prostate Cancer
Advertisement
E. David Crawford, MD from the University of Colorado Health Sciences Center Discusses Alternatives to Biopsy in Prostate Cancer
Advertisement
Related to this article
Aglatimagene besadenovec plus EBRT was linked to a 41% lower risk of prostate cancer recurrence or death, alongside durable immune activity.
Jason Hafron, MD, discusses the emotional, clinical, and financial burden of false positive cancer screening results and improved risk stratification.
Advertisement
Advertisement
Trending on OncLive
1
Epcoritamab Plus R-CHOP Meets PFS End Point in Newly Diagnosed DLBCL
2
‘Our Impact Will Be Broad and Transformative’: Wells Messersmith, MD, Takes the Reins at CU Anschutz Cancer Center
3
Botensilimab Plus Balstilimab Yields Durable OS in Recurrent Ovarian Cancer
4
FSHR-Directed CAR T-Cell Therapy Yields Instance of Stable Disease in Recurrent Ovarian Cancer
5